Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

5alpha-reductase inhibitors/finasteride

E Stoner1

  • 1Merck Research Laboratories, Department of Clinical Research, Rahway, New Jersey 07065-0900, USA.

The Prostate. Supplement
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia.

Urology·2002
Same author

5 alpha-Reductase inhibitors.

Advances in protein chemistry·2001
Same author

Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials.

European urology·2000
Same author

Drug points: prolonged cholestasis associated with irbesartan.

BMJ (Clinical research ed.)·2000
Same author

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group.

Urology·1999
Same author

Long-term effects of finasteride on prostate tissue composition.

Urology·1999

Finasteride effectively treats benign prostatic hyperplasia (BPH) by reducing prostate size and improving urinary flow. Long-term studies show sustained safety and efficacy for this BPH medication.

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Benign prostatic hyperplasia (BPH) involves prostate enlargement and urinary obstruction.
  • Dihydrotestosterone (DHT) is a key promoter of prostate growth.

Purpose of the Study:

  • To review the long-term safety and efficacy of finasteride for symptomatic BPH.
  • Evaluate finasteride's impact on prostate volume, DHT, PSA, and urinary flow.

Main Methods:

  • Two multi-center, placebo-controlled studies evaluated finasteride's efficacy over 12 months.
  • An open-label extension study followed patients treated with finasteride for up to 3 years.

Main Results:

  • Finasteride (5 mg daily) significantly reduced prostate volume, DHT, and PSA levels.
  • Maximum urinary flow rates and symptom scores improved with finasteride treatment.

Related Experiment Videos

  • Finasteride was well-tolerated over the 3-year treatment period.

    • Conclusions:

    • Finasteride is a safe and effective long-term treatment for symptomatic BPH.
    • The drug offers a valuable therapeutic option for managing prostate enlargement and associated urinary symptoms.